55.50
2.86%
-1.52
Biohaven Ltd stock is currently priced at $55.50, with a 24-hour trading volume of 355.95K.
It has seen a -2.86% decreased in the last 24 hours and a +17.10% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $56.10 pivot point. If it approaches the $55.14 support level, significant changes may occur.
Biohaven Ltd Stock (BHVN) Financials Data
Biohaven Ltd (BHVN) Net Income 2023
BHVN net income (TTM) was -$408.17 million for the quarter ending December 31, 2023, a +28.43% increase year-over-year.
Biohaven Ltd (BHVN) Cash Flow 2023
BHVN recorded a free cash flow (TTM) of -$334.77 million for the quarter ending December 31, 2023, a +1.18% increase year-over-year.
Biohaven Ltd (BHVN) Earnings per Share 2023
BHVN earnings per share (TTM) was -$5.72 for the quarter ending December 31, 2023, a +57.64% growth year-over-year.
Biohaven Ltd Stock (BHVN) Latest News
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Benzinga
Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky
MarketWatch
Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky
MarketWatch
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
Zacks Investment Research
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
About Biohaven Ltd
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.
Cap:
|
Volume (24h):